148 related articles for article (PubMed ID: 22753760)
1. Oxazolinodoxorubicin - a promising new anthracycline.
Lukawska M; Klopotowska D; Milczarek M; Wietrzyk J; Studzian K; Szmigiero L; Porebska A; Oszczapowicz I
Anticancer Res; 2012 Jul; 32(7):2959-65. PubMed ID: 22753760
[TBL] [Abstract][Full Text] [Related]
2. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
3. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
[TBL] [Abstract][Full Text] [Related]
4. Biological properties of new derivatives of daunorubicin.
Wasowska-Lukawska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
In Vivo; 2007; 21(2):413-6. PubMed ID: 17436596
[TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of a new bisintercalating anthracycline antibiotic.
Chaires JB; Leng F; Przewloka T; Fokt I; Ling YH; Perez-Soler R; Priebe W
J Med Chem; 1997 Jan; 40(3):261-6. PubMed ID: 9022792
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.
Geroni C; Ripamonti M; Arrigoni C; Fiorentini F; Capolongo L; Moneta D; Marchini S; Della Torre P; Albanese C; Lamparelli MG; Ciomei M; Rossi R; Caruso M
Cancer Res; 2001 Mar; 61(5):1983-90. PubMed ID: 11280756
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies.
Rajendra Prasad VV; Peters GJ; Lemos C; Kathmann I; Mayur YC
Eur J Pharm Sci; 2011 Jul; 43(4):217-24. PubMed ID: 21565270
[TBL] [Abstract][Full Text] [Related]
9. [14-O-hemiesters and 13-hydrazones of anthracyline antibiotics of the daunorubicin series. Synthesis and cytostatic activity with respect to tumor cells sensitive or resistant to doxorubicin].
Povarov LS; Leont'eva OV; Bernaki PD; Olsuf'eva EN; Salimova EI; Pera P; Preobrazhenskaia MN
Bioorg Khim; 1995 Dec; 21(12):925-32. PubMed ID: 8602889
[TBL] [Abstract][Full Text] [Related]
10. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
11. A new daunomycin-peptide conjugate: synthesis, characterization and the effect on the protein expression profile of HL-60 cells in vitro.
Orbán E; Manea M; Marquadt A; Bánóczi Z; Csík G; Fellinger E; Bosze S; Hudecz F
Bioconjug Chem; 2011 Oct; 22(10):2154-65. PubMed ID: 21950465
[TBL] [Abstract][Full Text] [Related]
12. In vitro studies on anthracycline haloderivatives.
Facchinetti T; Geroni C; Fumagalli A; Giuliani FC
Drugs Exp Clin Res; 1986; 12(8):657-61. PubMed ID: 3463498
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect.
Schlage P; Mezo G; Orbán E; Bosze S; Manea M
J Control Release; 2011 Dec; 156(2):170-8. PubMed ID: 21864594
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory activity of four demethoxy fluorinated anthracycline analogs against five human-tumor cell lines.
Horton D; Khare A
Bioorg Med Chem Lett; 2010 Nov; 20(21):6179-81. PubMed ID: 20850305
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activities of a 3'-azido analogue of Doxorubicin against drug-resistant cancer cells.
Yu S; Zhang G; Zhang W; Luo H; Qiu L; Liu Q; Sun D; Wang PG; Wang F
Int J Mol Sci; 2012; 13(3):3671-3684. PubMed ID: 22489175
[TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of daunorubicin analogues containing truncated aromatic cores and unnatural monosaccharide residues.
Fan E; Shi W; Lowary TL
J Org Chem; 2007 Apr; 72(8):2917-28. PubMed ID: 17373847
[TBL] [Abstract][Full Text] [Related]
18. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells.
Côme MG; Skladanowski A; Larsen AK; Laurent G
Br J Cancer; 1999 Mar; 79(7-8):1090-7. PubMed ID: 10098741
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of anthracyclines by cellular peroxidase.
Reszka KJ; Wagner BA; Teesch LM; Britigan BE; Spitz DR; Burns CP
Cancer Res; 2005 Jul; 65(14):6346-53. PubMed ID: 16024637
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics.
Studzian K; Wasowska M; Piestrzeniewicz MK; Wilmańska D; Szmigiero L; Oszczapowicz I; Gniazdowski M
Neoplasma; 2001; 48(5):412-8. PubMed ID: 11845988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]